KYOWA HAKKO KOGYO CO., LTD. Patent applications |
Patent application number | Title | Published |
20140193496 | INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS - An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 μm, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape. | 07-10-2014 |
20120046311 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF - Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: | 02-23-2012 |
20100280023 | THIAZOLE DERIVATIVES - It is intended to provide an adenosine A | 11-04-2010 |
20100267796 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - The present invention provides a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a compound having an adenosine uptake inhibitory activity, a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a tricyclic compound represented by formula (I) | 10-21-2010 |
20100248255 | NOVEL PEPTIDES - The present invention provides novel peptides with circulation-modulating activity. These peptides are useful as circulation-modulating agents and vasopressors because of their circulation-modulating activity, and can be used for treating diseases of the circulatory system such as myocardial infarction, ischemic heart disease, cerebral infarction, or the like. | 09-30-2010 |
20100234308 | WAKE-UP REMEDY - A wake-up remedy that for persons with the subjective symptoms of feeling languid after wake-up, having a hard time awaking, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a wake-up remedy containing alanylglutamine or its salt as an active ingredient. | 09-16-2010 |
20100223686 | MOUSE IN WHICH GENOME IS MODIFIED - A mouse or progenies thereof in which genome is modified so as to have decreased or deleted activity of an enzyme relating to modification of a sugar chain in which the 1-position of fucose is bound to the 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked complex sugar chain. | 09-02-2010 |
20100184163 | METHOD FOR PRODUCTION OF L-GLUTAMINE - A polypeptide comprising an amino acid sequence in which one or more amino acids are deleted, substituted or added in the amino acid sequence of a glutamine synthetase 2 derived from a microorganism belonging to a coryneform bacterium, wherein the coryneform bacterium producing the polypeptide has L-glutamine productivity, a DNA encoding the polypeptide, a recombinant DNA comprising the DNA, a microorganism comprising the DNA or the recombinant DNA, and a process for producing L-glutamine using the microorganism are provided. | 07-22-2010 |
20100168140 | Easily Absorbable Oral Preparations of Xanthine Derivatives - An object of the present invention is to provide an easily absorbable oral preparation containing a xanthine derivative or a pharmaceutically acceptable salt thereof and a fatty acid or a fatty acid derivative for the purpose of providing an easily absorbable oral preparation containing the xanthine derivative of which absorbability has been enhanced by dissolving the xanthine derivative that shows adenosine A | 07-01-2010 |
20100168040 | MUSCLE FATIGUE REMEDY - A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to acute exercise, lower back pain and stiffness in the shoulder attributed to taking of a certain posture over a prolonged period of time, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a muscle fatigue remedy containing alanylglutamine or its salt as an active ingredient. | 07-01-2010 |
20100167397 | ENDOCRINE CELL LINES AND METHOD OF USING THE SAME - In accordance with the present invention, there are provided (1) various cell lines derived from hypothalamus and Langerhans islets of mammals, (2) process for producing an active peptide and expression cloning system of active peptide precursor gene using the cell line as a host, (3) a method of screening or evaluating a substance capable of acting on the cells using the cell line, (4) a method of screening or isolating a useful gene or useful peptide using the cell line and (5) a highly-sensitive and simple assay system for GPCR ligand used in the above expression cloning system. | 07-01-2010 |
20100113468 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. | 05-06-2010 |
20100062486 | NOVEL PROTEIN AND DNA ENCODING THE PROTEIN - The present invention provides a protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for proteins of the amino acid sequences as shown in SEQ ID NOS: 4 to 6), and a process for industrially advantageously producing a compound that inhibits HMG-CoA reductase and has an action to decrease serum cholesterol, using DNA encoding the protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for DNA encoding the protein comprising the amino acid sequence as shown in SEQ ID NO: 4). | 03-11-2010 |
20090286284 | METHOD OF PURIFYING CYTIDINE DIPHOSPHATE CHOLINE - A method of purifying cytidine diphosphate choline, which comprises contacting a cytidine diphosphate choline solution containing a nucleic acid analogue and having a pH of not less than 0.5 and not more than 5.0 with an H-type strongly acidic cation exchange resin, and eluting cytidine diphosphate choline adsorbed onto the resin with water or an aqueous solution having an ion concentration of not more than 0.1 mol/L to separate and purify the cytidine diphosphate choline. | 11-19-2009 |
20090269806 | PROCESS FOR PRODUCING DIPEPTIDES - The present invention provides a process for producing a dipeptide which comprises culturing in a medium a microorganism which has the ability to produce a protein having the activity to form the dipeptide from one or more kinds of amino acids and which has the ability to produce at least one of said one or more kinds of amino acids, allowing the dipeptide to form and accumulate in the medium, and recovering the dipeptide from the medium. | 10-29-2009 |
20090258007 | Anti-Perp Antibody - The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP. | 10-15-2009 |
20090252723 | Remedy for endometriosis - The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient. | 10-08-2009 |
20090247522 | Hsp90 FAMILY PROTEIN INHIBITORS - The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): | 10-01-2009 |
20090232917 | COMPOSITION FOR RELIEVING SUBJECTIVE SYMPTOMS OF FATIGUE - There has been a demand in the marketplace for medicines, functional foods and so on which can relieve subjective symptoms of fatigue in persons having these subjective symptoms, and enabling the persons to have productive days. That is, an object of the present invention is to provide a composition for relieving subjective symptoms of fatigue. According to the present invention, a safe and effective composition for relieving subjective symptoms of fatigue which contains ornithine or a salt thereof as an active ingredient can be provided. | 09-17-2009 |
20090197303 | PROCESS FOR PRODUCING DIPEPTIDES - The present invention provides: a protein having dipeptide-synthesizing activity; DNA encoding the protein; a recombinant DNA comprising the DNA; a transformant transformed with the recombinant DNA; a process for producing the protein having dipeptide-synthesizing activity using the transformant or the like; a process for producing a dipeptide using the protein having dipeptide-synthesizing activity; and a process for producing a dipeptide using, as an enzyme source, a culture of a transformant or a microorganism which produces the protein having dipeptide-synthesizing activity or the like. | 08-06-2009 |
20090191589 | PROCESS FOR PRODUCING DIPEPTIDES - The present invention provides a protein which catalyzes the synthesis of a dipeptide different from L-Ala-L-Ala, a process for producing the protein which catalyzes the synthesis of a dipeptide, a process for producing a dipeptide using the protein which catalyzes the synthesis of a dipeptide, and a process for producing the dipeptide using a culture of a microorganism producing the protein which catalyzes the synthesis of a dipeptide or the like as an enzyme source. | 07-30-2009 |
20090181948 | DIAMINE DERIVATIVE - The present invention provides a diamine derivative or the like represented by the general formula (I): | 07-16-2009 |
20090176780 | NITROGENOUS HETEROCYCLIC COMPOUNDS - The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. | 07-09-2009 |
20090176760 | TRICYCLIC COMPOUNDS - The present invention provides a PPAR γ agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) | 07-09-2009 |
20090148916 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR - The present invention relates to a protein derived from a microorganism belonging to the genus | 06-11-2009 |
20090137583 | 2-AMINOQUINAZOLINE DERIVATIVES - The present invention provides 2-aminoquinazoline derivatives represented by formula (I): | 05-28-2009 |
20090130708 | DIPEPTIDE CRYSTALS AND PROCESS FOR PRODUCTION THEREOF - The present invention provides: (1) crystals of a dipeptide which do not substantially comprise a dipeptide comprising D-amino acid as a constituent or a polypeptide consisting of three or more amino acids; and (2) crystals of a dipeptide which do not substantially comprise a dipeptide comprising D-amino acid as a constituent, a polypeptide consisting of three or more amino acids, or an amino acid amide; and a process for producing the dipeptide crystals. | 05-21-2009 |
20090123980 | PROCESS FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE - The present invention provides a polypeptide which has: (i) an amino acid sequence wherein one or more amino acid residues are substituted in the region at positions 20 to 38 from the N terminus of the amino acid sequence shown in SEQ ID NO: 1; or (ii) an amino acid sequence wherein one or more amino acid residues are substituted in the region at positions 20 to 38 from the N terminus of the amino acid sequence shown in SEQ ID NO: 1 and one or more amino acid residues are deleted, substituted or added in the region at positions 1 to 19 or 39 to 294; and which has N-acetylglutamate kinase activity. | 05-14-2009 |
20090105277 | AGENT FOR PREVENTING AND/OR TREATING MOVEMENT DISORDER - For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine A | 04-23-2009 |
20090094710 | Mouse in Which Genome is Modified - A mouse or progenies thereof in which genome is modified so as to have decreased or deleted activity of an enzyme relating to modification of a sugar chain in which the 1-position of fucose is bound to the 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked complex sugar chain. | 04-09-2009 |
20090082594 | CRYSTALS OF L-ORNITHINE AND PROCESS FOR PRODUCING THE SAME - The present invention provides crystals of L-ornithine and a process for producing the crystals of L-ornithine including the steps of (i) exposing L-ornithine or a salt thereof, a composition comprising L-ornithine or a salt thereof, or a solution containing L-ornithine, a salt thereof, or the composition to a cation exchange resin to adsorb L-ornithine onto the cation exchange resin; (ii) eluting L-ornithine from the cation exchange resin on which L-ornithine is adsorbed with an aqueous alkaline solution, and removing an alkaline component from the resulting eluate to prepare an aqueous L-ornithine solution; and (iii) mixing the aqueous L-ornithine solution with a hydrophilic organic solvent, and crystallizing L-ornithine from the resulting mixed solution. | 03-26-2009 |
20090082348 | INDAZOLE DERIVATIVES - The present invention provides a compound represented by Formula (I): | 03-26-2009 |
20090082305 | METHOD OF IMPROVING STORAGE STABILITY OF SUBSTANCE - The present invention relates to a method of improving storage stability of reduced form of nicotinamide adenine dinucleotide, reduced form of nicotinamide adenine dinucleotide phosphate, or a salt thereof, or ascorbic acid, an ascorbic acid derivative, or a salt thereof, which comprises allowing the substance to coexist with an L-arginine acidic amino acid salt, a composition containing the substance and an L-arginine acidic amino acid salt, a process for producing the composition, and a method of storing the substance in the presence of an L-arginine acidic amino acid salt. | 03-26-2009 |
20090081739 | PROCESS FOR PRODUCING AMINO ACIDS - The present invention provides: a process for producing an amino acid which comprises adding crystals of the amino acid having an average particle size of 1 to 120 μm to a medium so that the concentration of the crystals of the amino acid becomes 0.5 g/l or more, culturing a microorganism having the ability to produce the amino acid in the medium, allowing crystals of the amino acid to form and accumulate in the medium, and recovering the crystals of the amino acid from the culture; and a process for producing an amino acid which comprises adding crystals of the amino acid to a medium so that the total surface area of the crystals of the amino acid in the medium becomes 0.02 m | 03-26-2009 |
20090069568 | METHOD FOR PRODUCING INDAZOL-3-YLMETHYL PHOSPHONIUM SALT - The present invention provides a method for producing an indazol-3-ylmethyl phosphonium salt represented by Formula (IV): | 03-12-2009 |
20090069403 | COMPOSITION AND METHOD FOR REDUCING ALLERGEN - This invention relates to an allergen-reducing composition comprising a hydroxyproline derivative, a polymer thereof, or a salt of such a derivative or polymer, which is capable of reducing the allergenicity of mites, pollens, or other allergens and is capable of imparting functions of reducing allergenicity to fibers or textiles such as a carpet, a tatami mat, a bed cloth, a curtain, clothing, a stuffed animal, a mask, a filter material, or a dust bag for an electric vacuum cleaner without discoloration; and a method for reducing allergens using such composition. | 03-12-2009 |
20090068720 | USEFUL POLYPEPTIDES - The present invention provides a novel polypeptide having a β1,3-N-acetylglucosaminyl transferase activity; a method for producing the polypeptide; a DNA which encodes the polypeptide; a recombinant vector into which the DNA is inserted; a transformant comprising the recombinant vector; a method for producing a sugar chain or complex carbohydrate, using the polypeptide; a method for producing a sugar chain or complex carbohydrate, using the transformant; an antibody which recognizes the polypeptide; a method for screening a substance which changes the expression of the gene which encodes the polypeptide; and a method for screening a substance which changes the activity of the polypeptide. | 03-12-2009 |
20090068713 | PROCESS FOR PRODUCING GAMMA-GLUTAMYLAMIDE COMPOUNDS - The present invention provides a process for producing a γ-glutamylamide compound, which comprises forming the γ-glutamylamide compound from a glutamyl donor and an amine compound using γ-glutamylcysteine synthetase, preferably γ-glutamylcysteine synthetase derived from a microorganism, or a culture of cells having the enzyme or a treated culture as an enzyme source. | 03-12-2009 |
20090062371 | ORAL PREPARATION FOR PROMOTING SYNTHESIS OF TISSUE COLLAGEN - An object of the present invention is to provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which is safe and has an excellent effect. The present invention can provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which comprises hydroxyproline or a salt thereof as an active ingredient. | 03-05-2009 |
20090054685 | Methods for Purifying Amino Acids - In the method for separating and purifying a basic amino acid, preferably the basic amino acid selected from arginine, lysine or ornithine from a culture containing the amino acid, the culture containing the a basic amino acid and microbial cells, preferably the culture whose pH is 4 to 10, is charged onto the top of a column filled with a weak acid cation exchange resin whose particle size is 300 μm or more and passed therethrough, and then an eluent is poured into the column from the top thereof whereby accomplishing the separation and the purification of the basic amino acid. | 02-26-2009 |
20090054508 | IGF-1R INHIBITOR - The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): | 02-26-2009 |
20090054407 | Nitrogen-containing heterocyclic compound - The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): | 02-26-2009 |
20090053798 | Method of Improving Storage Stability of Dried Microorganisms - The present invention relates to a method of improving storage stability of dried microorganisms, such as dried lactic acid bacteria, by allowing the dried microorganisms to coexist with an L-arginine acidic amino acid salt, a composition comprising dried microorganisms and an L-arginine acidic amino acid salt and a process for producing the same, and a method of storing dried microorganisms in the presence of an L-arginine acidic amino acid salt. The storage stability of dried microorganisms can be improved by allowing the dried microorganisms to coexist with an L-arginine acidic amino acid salt. | 02-26-2009 |
20090048253 | BENZENOID ANSAMYCIN DERIVATIVE - The present invention provides a benzenoid ansamycin derivative represented by Formula (I) | 02-19-2009 |
20090047706 | PROCESS FOR PRODUCING DIPEPTIDES - The present invention provides: a protein having dipeptide-synthesizing activity; DNA encoding the protein; a recombinant DNA comprising the DNA; a transformant transformed with the recombinant DNA; a process for producing the protein having dipeptide-synthesizing activity using the transformant or the like; a process for producing a dipeptide using the protein having dipeptide-synthesizing activity; and a process for producing a dipeptide using, as an enzyme source, a culture of a transformant or a microorganism which produces the protein having dipeptide-synthesizing activity or the like. | 02-19-2009 |
20090041835 | METHOD OF INHIBITING LEAKAGE OF DRUG ENCAPSULATED IN LIPOSOMES - The present invention provides a method of inhibiting the leakage of a drug encapsulated in liposomes, which comprises satisfying at least two requirements selected from the group consisting of the following three requirements: using at least two lipid bilayers of the liposomes, controlling the average particle size of the liposomes to 120 nm or more, and using lipid having a phase transition temperature higher than in vivo temperature as lipid constituting the liposomes. Also, the present invention provides a liposome preparation which is stable in vivo and satisfies at least two requirements selected from the group consisting of the following three requirements: the number of lipid bilayers of the liposomes is at least two, the liposomes have an average particle size of 120 nm or more, and lipid constituting the liposomes has a phase transition temperature higher than in vivo temperature. | 02-12-2009 |
20090036693 | METHOD OF PURIFYING UBIQUINONE-10 - According to the present invention, a method of purifying ubiquinone-10, which includes separating and removing a substance structurally similar to ubiquinone-10 contained in a starting material solution containing ubiquinone-10 by the use of a porous crosslinked acrylic polymer, more preferably, a method of purifying ubiquinone-10 by separating and removing a substance structurally similar to ubiquinone-10 contained in a starting material solution, which includes feeding a starting material solution containing ubiquinone-10 in a simulated moving bed chromatography apparatus wherein a solution can circulate in one direction in a packed-bed wherein a porous crosslinked acrylic polymer is packed, and flowing an eluent in the packed-bed in one direction, is provided. | 02-05-2009 |
20090028937 | TABLET COMPRISING ORNITHINE HYDROCHLORIDE - The present invention has an object to provide a tablet capable of comprising ornithine hydrochloride in a higher content; and a process for producing the same, and provides the tablet comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin; and the process for producing a tablet comprising ornithine hydrochloride, which comprises compression molding a mixture comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin by a direct tableting method. | 01-29-2009 |
20090023755 | USE OF ISTRADEFYLLINE FOR TREATING BEHAVIORAL DISORDERS - The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like. | 01-22-2009 |
20090012060 | Antitumor Agent - The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): | 01-08-2009 |
20090012051 | EXTERNAL PREPARATION - The present invention provides an external preparation which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1′-cyclopentane] represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, comprising 0.5 to 15% by mass of a solvent component in which the solubility of the active ingredient is 4 mg/mL or more, and the like. | 01-08-2009 |
20090011003 | Composition for Suppressing Expression of Target Gene - The present invention has its object to provide a composition for suppressing the expression of a target gene and the like, and provides a composition, comprising an RNA-encapsulated liposome which comprises complex particles comprising as constituent components a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles, wherein constituent components of the lipid membrane can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible, and the like. | 01-08-2009 |
20090010999 | Complex Particles and Coated Complex Particles - The present invention provides, for example, a method of inhibiting aggregation of complex particles in which a drug is adhered to lead particles, characterized by containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant in the lead particles. Further, it provides, for example, a method of producing the complex particles in which a nucleic acid as a drug or a drug is adhered to lead particles, comprising the step of dispersing or dissolving the nucleic acid as a drug or the drug and an adhesion-competitive agent so as to be contained in a liquid in which the lead particles containing a lipid derivative or a fatty acid derivative of one or more substance(s) selected from sugars, peptides, nucleic acids and water-soluble polymers or a surfactant are dispersed, thereby allowing the nucleic acid as a drug or the drug and the adhesion-competitive agent adhered to the lead particles. | 01-08-2009 |
20090004186 | EFFECTOR FUNCTION ENHANCED RECOMBINANT ANTIBODY COMPOSITION - The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. | 01-01-2009 |
20080305151 | Dipeptide-Comprising Composition for Oral Administration - The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula: | 12-11-2008 |
20080267953 | Anti-perp recombinant antibody - An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene. | 10-30-2008 |
20080262049 | Therapeutic Agent for Hematopoietic Tumor - A therapeutic and/or prophylactic agent for a hematopoietic tumor, which comprises a thiadiazoline derivative represented by the general formula (I), or a pharmaceutically acceptable salt thereof: | 10-23-2008 |
20080261273 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITORS - The present invention relates to processes for producing compounds by using a protein derived from a microorganism belonging to the genus | 10-23-2008 |
20080241960 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN - Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided. | 10-02-2008 |
20080227141 | PROCESS FOR PRODUCING ISOPRENOID COMPOUNDS BY MICROORGANISMS AND A METHOD FOR SCREENING COMPOUNDS WITH ANTIBIOTIC OR WEEDING ACTIVITY - The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles; the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway. | 09-18-2008 |
20080207706 | THIADIAZOLINE DERIVATIVE | 08-28-2008 |
20080201788 | Mouse in which genome is modified - A mouse or progenies thereof in which genome is modified so as to have decreased or deleted activity of an enzyme relating to modification of a sugar chain in which the | 08-21-2008 |